DOCSLIB.ORG

Society of Breast Imaging and American College of Radiology Recommendations for Imaging Screening for Breast Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Society of Breast Imaging and American College of Radiology Recommendations for Imaging Screening for Breast Cancer Society of Breast Imaging and American College of Radiology Recommendations for Imaging Screening for Breast Cancer A. BY IMAGING TECHNIQUE B. BY RISK FACTOR 1. Mammography 2. Ultrasound 1. Average Risk • Women at average risk for breast cancer a. Screening Mammography by Age (in Addition to Mammography) • Annual mammogram starting at age 40 – Annual screening from age 40 i. Age at Which Annual Screening • Can be considered in high-risk women Mammography Should Start for whom magnetic resonance imaging 2. High Risk (MRI) screening may be appropriate but • Women at increased risk for breast cancer Age 40 • BRCA1 or BRCA2 mutation carriers, untested who cannot have MRI for any reason – Women with certain BRCA1 or BRCA2 • Women at average risk first-degree relatives ofBRCA mutation carrier mutations or who are untested but – Annual mammogram and annual MRI have first-degree relatives (mothers, Younger Than Age 40 starting by age 30 but not before age 25 sisters, or daughters) who are proved to 3. MRI • BRCA1 or BRCA2 mutation carriers: by • Proven carriers of a deleterious BRCA mutation • Women with ≥20% lifetime risk for breast have BRCA mutations age 30, but not before age 25 • Yearly starting by age 30 (but not – Annually starting at age 30 cancer on the basis of family history before age 25) • Women with mothers or sister with • Untested first-degree relatives of proven – Annual mammography and annual MRI pre-menopausal breast cancer: by age BRCA mutation carriers starting by age 30 but not before age – Women with ≥20% lifetime risk for 30 but not before age 25, or 10 years 25, or 10 years before the age of the – Annually starting by age 30 breast cancer on the basis of family earlier than the age of diagnosis of youngest affected relative, whichever is history (both maternal and paternal) relative, whichever is later • Women with >20% lifetime risk for breast later • Yearly starting at age 30 (but not cancer on the basis of family history • Women with ≥20% lifetime risk for • History of chest irradiation received between before age 25), or 10 years earlier than – Annually starting by age 30 the age of diagnosis of the youngest breast cancer on the basis of family the ages of 10 and 30 affected relative, whichever is later history (both maternal and paternal): • Women with histories of chest irradiation – Annual mammogram and annual MRI yearly starting by age 30 but not before (usually as treatment for Hodgkin’s disease) starting 8 years after treatment; – Women with mothers or sisters with age 25, or 10 years earlier than the age – Annually starting 8 years after the mammography is not recommended pre-menopausal breast cancer of diagnosis of the youngest affected radiation therapy before age 25 • Yearly starting by age 30 (but not relative, whichever is later before age 25), or 10 years earlier than • Women with newly diagnosed breast • Personal history of breast cancer (invasive the age of diagnosis of the youngest • Women with histories of mantle radiation cancer and normal contralateral breast by carcinoma or DCIS), ovarian cancer, or affected relative, whichever is later received between the ages of 10 and 30: conventional imaging and physical biopsy diagnosis of lobular neoplasia or ADH beginning 8 years after the radiation examination – Annual mammography from time of – Women with histories of mantle therapy but not before age 25 – Single screening MRI of the contralateral diagnosis; either annual MRI or ultrasound radiation (usually for Hodgkin’s disease) breast at the time of diagnosis can also be considered; if screening MRI received between the ages of 10 and 30 • Women with biopsy-proven lobular neoplasia, ADH, DCIS, invasive breast is performed in addition to mammography, • Yearly starting 8 years after the • May be considered in women with cancer, or ovarian cancer regardless of age also performing screening ultrasound is radiation therapy, but not before age 25 between 15% and 20% lifetime risk for not necessary breast cancer on the basis of personal – Women with biopsy-proven lobular history of breast or ovarian cancer or neoplasia (lobular carcinoma in situ and ii. Age at Which Annual Screening With biopsy-proven lobular neoplasia or ADH atypical lobular hyperplasia), atypical Mammography Should Stop ductal hyperplasia (ADH), ductal • When life expectancy is <5 to 7 years on carcinoma in situ (DCIS), invasive breast the basis of age or comorbid conditions cancer or ovarian cancer • Yearly from time of diagnosis, regardless • When abnormal results of screening of age would not be acted on because of age or comorbid conditions — Excerpt from “Breast Cancer Screening with Imaging”; Lee et al; the Journal of the American College of Radiology The Breast Center of Suburban Imaging agrees with these recommendations (JACR); v7 • n1, January 2010.
Load more

Recommended publications
  • Understanding Hereditary Breast & Ovarian Cancer
    Understanding Hereditary Breast & Ovarian Cancer – the BRCA genes understanding hereditary breast & ovarian cancer – the brca genes 3 Contents Introduction Introduction ___________________________________________________________ 3 The purpose of this booklet is to review the information How are cancer & genes related? _________________________________________ 4 about hereditary breast and ovarian cancer as discussed in What is known about hereditary cancer? ___________________________________ 5 a genetic counselling session. You may also wish to use this Is my family at risk? _____________________________________________________ 6 booklet to help you share information with other family members. The BRCA1 and BRCA2 genes _____________________________________________ 7 What happens if there is a mutation in a BRCA gene? _________________________ 7 This booklet was prepared by staff of the Hereditary Cancer What happens if a person inherits a BRCA gene mutation? ____________________ 8 Program, based on information that was current at the time What are the risks for the children of a BRCA gene mutation carrier? ___________ 9 of printing. What is the risk of cancer for a BRCA gene mutation carrier? __________________10 What is genetic testing? _________________________________________________ 11 Words that may be new to you are highlighted and are Who can have BRCA genetic testing? ______________________________________ 11 defined in the Glossary on page 28. How is BRCA genetic testing done? ________________________________________12 Results
    [Show full text]
  • Evaluation of Nipple Discharge
    New 2016 American College of Radiology ACR Appropriateness Criteria® Evaluation of Nipple Discharge Variant 1: Physiologic nipple discharge. Female of any age. Initial imaging examination. Radiologic Procedure Rating Comments RRL* Mammography diagnostic 1 See references [2,4-7]. ☢☢ Digital breast tomosynthesis diagnostic 1 See references [2,4-7]. ☢☢ US breast 1 See references [2,4-7]. O MRI breast without and with IV contrast 1 See references [2,4-7]. O MRI breast without IV contrast 1 See references [2,4-7]. O FDG-PEM 1 See references [2,4-7]. ☢☢☢☢ Sestamibi MBI 1 See references [2,4-7]. ☢☢☢ Ductography 1 See references [2,4-7]. ☢☢ Image-guided core biopsy breast 1 See references [2,4-7]. Varies Image-guided fine needle aspiration breast 1 Varies *Relative Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate Radiation Level Variant 2: Pathologic nipple discharge. Male or female 40 years of age or older. Initial imaging examination. Radiologic Procedure Rating Comments RRL* See references [3,6,8,10,13,14,16,25- Mammography diagnostic 9 29,32,34,42-44,71-73]. ☢☢ See references [3,6,8,10,13,14,16,25- Digital breast tomosynthesis diagnostic 9 29,32,34,42-44,71-73]. ☢☢ US is usually complementary to mammography. It can be an alternative to mammography if the patient had a recent US breast 9 mammogram or is pregnant. See O references [3,5,10,12,13,16,25,30,31,45- 49]. MRI breast without and with IV contrast 1 See references [3,8,23,24,35,46,51-55].
    [Show full text]
  • What You Should Know About Breast Cancer Screening
    Cancer AnswerLineTM WHAT YOU SHOULD KNOW ABOUT BREAST CANCER SCREENING Women should speak to their health care provider about their risk of breast cancer and whether a screening test is right for them, as well as to review the risks and benefits of screening. The purpose of screening is to find disease early; THE AMERICAN CANCER SOCIETY’S ideally before symptoms appear. Almost all diseases, RECOMMENDATIONS: including cancer, are easier to treat in an earlier • Women between 40 and 44 have the option to stage as opposed to an advanced stage. start screening with a mammogram every year. Women 45 to 54 should get mammograms every While experts may have different opinions regarding • year. when to begin mammography screening and at what frequency, all major U.S. organizations, • Women 55 and older can switch to a mammogram including the American Cancer Society, the every other year, or they can choose to continue National Comprehensive Cancer Network and the yearly mammograms. Screening should continue U.S. Preventive Services Task Force continue to as long as a woman is in good health and is recommend regular screening mammography to expected to live 10 more years or longer. reduce breast cancer mortality. Breast cancer • All women should understand what to expect mortality rates have continued to decrease in the when getting a mammogram for breast cancer United States due to advances in screening and screening—what the test can and cannot do. treatment over the last 20 years. These recommendations apply to asymptomatic Breast cancer screening is broken down into women aged 40 years or older who do not have different classifications based the patient’s age, level preexisting breast cancer or a previously diagnosed of risk (how likely they are to get breast cancer), and high-risk breast lesion and who are not at high risk strength of the recommendation.
    [Show full text]
  • BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives
    cancers Review BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives Eleonora Molinaro, Kalliopi Andrikou, Andrea Casadei-Gardini * and Giulia Rovesti Department of Oncology and Hematology, Division of Oncology, University of Modena and Reggio Emilia, 41121 Modena, Italy; [email protected] (E.M.); [email protected] (K.A.); [email protected] (G.R.) * Correspondence: [email protected] Received: 10 October 2020; Accepted: 11 November 2020; Published: 12 November 2020 Simple Summary: BRCA gene mutations are progressively gaining more attention in the context of gastrointestinal malignancies, especially in pancreatic cancer where their identification can have both therapeutic and surveillance relevance. Abstract: A strong association between pancreatic cancer and BRCA1 and BRCA2 mutations is documented. Based on promising results of breast and ovarian cancers, several clinical trials with poly (ADP-ribose) polymerase inhibitors (PARPi) are ongoing for gastrointestinal (GI) malignancies, especially for pancreatic cancer. Indeed, the POLO trial results provide promising and awaited changes for the pancreatic cancer therapeutic landscape. Contrariwise, for other gastrointestinal tumors, the rationale is currently only alleged. The role of BRCA mutation in gastrointestinal cancers is the subject of this review. In particular, we aim to provide the latest updates about novel therapeutic strategies that, exploiting DNA repair defects, promise to shape the future therapeutic scenario of GI cancers. Keywords: BRCA1; BRCA2; gastrointestinal cancers; HRD; pancreatic cancer; Olaparib; PARP inhibitors; surveillance 1. Introduction BRCA1 and BRCA2 are famous tumor susceptibility genes. They encode for proteins playing a crucial role in the correct repair of damaged DNA. Indeed, these genes are key components of the homologous recombination (HR) pathway [1].
    [Show full text]
  • Genetic Testing for BRCA1 and BRCA2: Information for Texas Health Care Professionals
    Genetic Testing for BRCA1 and BRCA2: Information for Texas Health Care Professionals How common are BRCA1 and BRCA2 mutations in the general population? Inherited mutations in BRCA1 and BRCA2 are relatively uncommon in the general population. The carrier frequency is estimated to range from 1 in 300 to 1 in 800.1,3 Certain ethnic groups have been shown to have a higher carrier frequency (i.e., 1 in 40 for individuals of Ashkenazi Jewish descent). What percentage of breast and ovarian cancer cases are estimated to be caused by BRCA1 and BRCA2 mutations? Five to 10 percent of all breast cancer cases and up to 14 percent of all ovarian cancer cases are thought to be caused by BRCA1 and BRCA2 mutations.1,2,3,4 Can BRCA1 and BRCA2 mutations be inherited from either side of the family? Yes, either parent can pass along a BRCA1 or BRCA2 mutation. Therefore, it is important for clinicians to obtain a complete cancer history on both the maternal and the paternal sides of the family when assessing genetic risk.4 Which patients should I consider referring to a genetic counselor for risk assessment and to discuss the option of genetic testing for BRCA1 and BRCA2 mutations? Most individuals do not have a mutation in the BRCA1 or BRCA2 gene. While specific indications for genetic counseling and testing vary among professional organizations, certain aspects of your patient’s personal and/or family history may increase his or her likelihood of carrying a BRCA1 or BRCA2 mutation. The indications below are to be used as a guide and are not a substitute for clinical judgment.
    [Show full text]
  • BRCA1 and BRCA2 in Men
    BRCA1 and BRCA2 in Men Everyone has BRCA1 and BRCA2 genes. These genes help repair damage to the DNA within cells. However, some individuals inherit a mutation in one of their BRCA genes, which increases their risk for certain cancers, including breast (female and male), ovarian, pancreatic and prostate cancers, as well as melanoma. Those who test positive for a gene mutation have options available to lower and manage their cancer risks. Man can carry BRCA1 or BRCA2 gene mutations and can be at increased risk for certain cancers. While cancer risks in male BRCA mutation carriers are not as dramatically elevated as those of female BRCA mutation carriers, cancer risk management and early detection are crucial. It is important for both men and women to remember that a family history of breast, ovarian, prostate or pancreatic cancers on their father’s side of the family may indicate a hereditary gene mutation. Many people mistakenly believe a family history of breast or ovarian cancer only matters on their mother’s side of the family. Men can inherit a BRCA gene mutation from their mother or father and can pass on their BRCA gene mutation to their male and female children. Medical management for men with BRCA1/2 mutations changes at age 35–40. Starting at age 35, male BRCA mutation carriers should begin yearly clinical breast exams with a physician. At age 40, prostate cancer screenings are recommended for BRCA2 carriers and considered for BRCA1 carriers. Men with a BRCA mutation and a family history of pancreatic cancer or melanoma should speak to a physician to develop a personalized screening plan for those cancers.
    [Show full text]
  • Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Evidence Synthesis
    Evidence Synthesis Number 37 Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Evidence Synthesis Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-02-0024 Task Order No. 2 Technical Support of the U.S. Preventive Services Task Force Prepared by: Oregon Evidence-based Practice Center Portland, Oregon Investigators Heidi D. Nelson, MD, MPH Laurie Hoyt Huffman, MS Rongwei Fu, PhD Emily L. Harris, PhD, MPH Miranda Walker, BA Christina Bougatsos, BS September 2005 This report may be used, in whole or in part, as the basis of the development of clinical practice guidelines and other quality enhancement tools, or a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied. AHRQ is the lead Federal agency charged with supporting research designed to improve the quality of health care, reduce its cost, address patient safety and medical errors, and broaden access to essential services. AHRQ sponsors and conducts research that provides evidence-based information on health care outcomes; quality; and cost, use, and access. The information helps health care decisionmakers—patients and clinicians, health system leaders, and policymakers—make more informed decisions and improve the quality of health care services. Preface The Agency for Healthcare Research and Quality (AHRQ) sponsors the development of Systematic Evidence Reviews (SERs) and Evidence Syntheses through its Evidence-based Practice Program. With guidance from the U.S.
    [Show full text]
  • Breast Imaging Faqs
    Breast Imaging Frequently Asked Questions Update 2021 The following Q&As address Medicare guidelines on the reporting of breast imaging procedures. Private payer guidelines may vary from Medicare guidelines and from payer to payer; therefore, please be sure to check with your private payers on their specific breast imaging guidelines. Q: What differentiates a diagnostic from a screening mammography procedure? Medicare’s definitions of screening and diagnostic mammography, as noted in the Centers for Medicare and Medicaid’s (CMS’) National Coverage Determination database, and the American College of Radiology’s (ACR’s) definitions, as stated in the ACR Practice Parameter of Screening and Diagnostic Mammography, are provided as a means of differentiating diagnostic from screening mammography procedures. Although Medicare’s definitions are consistent with those from the ACR, the ACR's definitions of screening and diagnostic mammography offer additional insight into what may be included in these procedures. Please go to the CMS and ACR Web site links noted below for more in- depth information about these studies. Medicare Definitions (per the CMS National Coverage Determination for Mammograms 220.4) “A diagnostic mammogram is a radiologic procedure furnished to a man or woman with signs and symptoms of breast disease, or a personal history of breast cancer, or a personal history of biopsy - proven benign breast disease, and includes a physician's interpretation of the results of the procedure.” “A screening mammogram is a radiologic procedure furnished to a woman without signs or symptoms of breast disease, for the purpose of early detection of breast cancer, and includes a physician’s interpretation of the results of the procedure.
    [Show full text]
  • ACOG: Practice Bulletin for Hereditary Breast and Ovarian Cancer
    ACOG PRACTICE BULLETIN Clinical Management Guidelines for Obstetrician–Gynecologists NUMBER 182, SEPTEMBER 2017 (Replaces Practice Bulletin Number 103, April 2009) Committee on Practice Bulletins–Gynecology, Committee on Genetics, Society of Gynecologic Oncology. This Practice Bulletin was developed by the American College of Obstetrician and Gynecologists’ Committee on Practice Bulletins–Gynecology and Committee on Genetics in collaboration with Susan C. Modesitt, MD, and Karen Lu, MD, and by the Society of Gynecologic Oncology in collaboration with Lee-may Chen, MD, and C. Bethan Powell, MD. Hereditary Breast and Ovarian Cancer Syndrome Hereditary breast and ovarian cancer syndrome is an inherited cancer-susceptibility syndrome characterized by mul- tiple family members with breast cancer, ovarian cancer, or both. Based on the contemporary understanding of the origins and management of ovarian cancer and for simplicity in this document, ovarian cancer also refers to fallopian tube cancer and primary peritoneal cancer. Clinical genetic testing for gene mutations allows more precise identifica- tion of those women who are at an increased risk of inherited breast cancer and ovarian cancer. For these individuals, screening and prevention strategies can be instituted to reduce their risks. Obstetrician–gynecologists play an impor- tant role in the identification and management of women with hereditary breast and ovarian cancer syndrome. If an obstetrician–gynecologist or other gynecologic care provider does not have the necessary knowledge or expertise in cancer genetics to counsel a patient appropriately, referral to a genetic counselor, gynecologic or medical oncologist, or other genetics specialist should be considered (1). More genes are being discovered that impart varying risks of breast cancer, ovarian cancer, and other types of cancer, and new technologies are being developed for genetic test- ing.
    [Show full text]
  • Insights Into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
    Published OnlineFirst January 24, 2019; DOI: 10.1158/2159-8290.CD-18-1177 REVIEW Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment Ana C. Garrido-Castro1,2, Nancy U. Lin1,2, and Kornelia Polyak1,2 ABSTRACT Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype to treat. To date, therapies directed to specific molecular targets have rarely achieved clinically meaningful improvements in outcomes of patients with TNBC, and chemo- therapy remains the standard of care. Here, we seek to review the most recent efforts to classify TNBC based on the comprehensive profiling of tumors for cellular composition and molecular features. Technologic advances allow for tumor characterization at ever-increasing depth, generating data that, if integrated with clinical–pathologic features, may help improve risk stratification of patients, guide treatment decisions and surveillance, and help identify new targets for drug development. Significance: TNBC is characterized by higher rates of relapse, greater metastatic potential, and shorter overall survival compared with other major breast cancer subtypes. The identification of biomarkers that can help guide treatment decisions in TNBC remains a clinically unmet need. Under- standing the mechanisms that drive resistance is key to the design of novel therapeutic strategies to help prevent the development of metastatic disease and, ultimately, to improve survival in this patient population. INTRODUCTION with TNBC, and chemotherapy remains the standard of care. Although many patients with early stages of TNBC are cured Breast cancer is the most frequently diagnosed cancer with chemotherapy, in those who develop metastatic disease, and the second most common cause of cancer mortality in median overall survival (OS) with current treatment options women worldwide (1).
    [Show full text]
  • The BRCA Guide
    BRCA Guide: Navigating Your Journey A guide to BRCA mutations and their influence on cancer from beBRCAware beBRCAware @beBRCAware @beBRCAware WHAT IS BRCA? Everyone is born with BRCA1 and BRCA2 genes. Normally, these genes ensure that cancerous cells don’t grow and multiply. However, these genes can be mutated, causing their function to change. Mutated BRCA genes are less likely to have control over cancerous cells, leading to an increased risk of ovarian, breast, prostate, and pancreatic cancer. Ovarian cancer can be deadly among women and those with a BRCA mutation are at an increased risk of developing this disease. If you have a BRCA1 mutation, you have a 39% chance of developing ovarian cancer by age 70. If you have a BRCA2 mutation, you have an 11% chance of developing ovarian cancer by age 70. WHY GET TESTED? If you have cancer: If you do not have cancer: Knowing your BRCA status can help your health Knowing your BRCA status will let you know if care team plan potential treatment options, such as you have an increased risk for developing certain targeted therapy. It can also help inform others in cancers. From there, you and your doctor can then your family about their own cancer risk. Remember, decide to screen for cancer more frequently or take you can get tested at any time—even after your preventive action. Finding out that you have a BRCA initial diagnosis. mutation can also prompt other family members to get tested to see if they are at risk. Talk to your doctor about getting BRCA tested BRCA Guide: Navigating Your Journey 1 YOUR FAMILY COULD BE AT RISK Because BRCA mutations may be hereditary, they can be passed down to family members regardless of gender.
    [Show full text]
  • Endometrial Cancer Occurence Five Years After Breast Cancer in BRCA2 Mutation Patient
    Case Report Obstet Gynecol Sci 2015;58(2):175-178 http://dx.doi.org/10.5468/ogs.2015.58.2.175 pISSN 2287-8572 · eISSN 2287-8580 Endometrial cancer occurence five years after breast cancer in BRCA2 mutation patient Sang Eun Oh1, Soo Hyun Kim1, Mee Seon Kim2, Min Kyu Kim3 1Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; Departments of 2Pathology and 3Obstetrics and Gynecology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea We recently experienced a case of endometrial cancer 5 years after the diagnosis of breast cancer in a patient with a mutation in the BRCA2 gene. A 55-year-old Korean woman who had a past history of breast cancer in her 50s underwent an operation for endometrial cancer. Final pathology confirmed stage Ia, and no adjuvant treatment was performed. After surgery, considering her history of sequential cancer occurrence, genetic counseling was offered. The result showed the BRCA2 variation of unknown significance mutation. This is the first case report of sequential cancers (endometrial and breast) in a patient with a BRCA2 mutation among a Korean population. Keywords: BRCA; Breast neoplasms; Endometrial neoplasms Introduction In breast cancer, the average lifetime risk is 65% and 45% in women with BRCA1 and BRCA2 mutations, respectively. In Endometrial cancer is one of the most common and curable ovarian cancer, the average lifetime risk is 39% and 11% in gynecologic cancers. It usually occurs in women over the age women with BRCA1 and BRCA2 mutations, respectively [6]. of 50 years. The risk factors for endometrial cancer are associ- Recently, BRCA genes have been studied in association with ated with exposure to unopposed estrogen, obesity, diabetes endometrial cancer.
    [Show full text]